Repros Therapeutics Inc. (NASDAQ:RPRX) had its price target decreased by S&P Equity Research from $0.49 to $0.39 in a report published on Monday.

Shares of Repros Therapeutics (NASDAQ RPRX) traded up $0.03 on Monday, reaching $0.46. The company had a trading volume of 195,489 shares, compared to its average volume of 624,918. Repros Therapeutics has a 12 month low of $0.26 and a 12 month high of $2.00.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.24. The company had revenue of $0.30 million during the quarter. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/21/repros-therapeutics-inc-rprx-price-target-cut-to-0-39-by-analysts-at-sp-equity-research.html.

An institutional investor recently raised its position in Repros Therapeutics stock. Allegis Investment Advisors LLC grew its holdings in Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 398,792 shares of the biotechnology company’s stock after purchasing an additional 32,602 shares during the period. Allegis Investment Advisors LLC owned about 1.49% of Repros Therapeutics worth $183,000 as of its most recent filing with the Securities & Exchange Commission. 13.13% of the stock is currently owned by hedge funds and other institutional investors.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.